Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
J Urol. 2012 Jan;187(1):74-9. doi: 10.1016/j.juro.2011.09.056. Epub 2011 Nov 16.
We compared clinical outcomes, and identified predictors of cancer specific and overall survival after radical cystectomy in patients with urothelial carcinoma with squamous differentiation and those with pure squamous cell carcinoma.
We reviewed data on 2,031 patients treated with radical cystectomy and pelvic lymph node dissection at a single high volume referral center. Of these patients 78 had squamous cell carcinoma and 67 had squamous differentiation. Survival estimates by histological subtype were described using Kaplan-Meier methods. Within histological subtypes pathological stage, nodal invasion, soft tissue margins, age and gender were evaluated as predictors of cancer specific survival and overall survival using univariate Cox regression.
Median followup was 44 months. Of 104 patient deaths 60 died of their disease. We did not find a statistically significant difference between survival curves of patients with squamous cell carcinoma and squamous differentiation (log rank overall survival p = 0.6, cancer specific survival p = 0.17). Positive soft tissue margins were associated with worse cancer specific survival (HR 6.92, 95% CI 2.98-16.10, p ≤0.0005) and overall survival (HR 3.68, 95% CI 1.84-7.35, p ≤0.0005) in patients with pure squamous cell carcinoma. Among patients with squamous differentiation, pelvic lymphadenopathy was associated with decreased overall survival (HR 2.52, 95% CI 1.33-4.77, p = 0.004) and cancer specific survival (HR 3.23, 95% CI 1.57-6.67, p = 0.002).
There appears to be no evidence of a difference in cancer specific survival or overall survival between patients with squamous cell carcinoma and those with squamous differentiation treated with radical cystectomy and pelvic lymph node dissection. Patients with squamous differentiation and tumor metastases to pelvic lymph nodes should be followed more closely, and adjuvant treatment should be considered to improve survival. Wide surgical resection is critical to achieve local tumor control and improve survival in patients with squamous cell carcinoma.
我们比较了在根治性膀胱切除术和盆腔淋巴结清扫术后患有尿路上皮癌伴鳞状分化和单纯鳞状细胞癌患者的临床结局,并确定了癌症特异性和总体生存率的预测因素。
我们回顾了在一个高容量转诊中心接受根治性膀胱切除术和盆腔淋巴结清扫术的 2031 名患者的数据。其中 78 名患者患有鳞状细胞癌,67 名患者患有鳞状分化。使用 Kaplan-Meier 方法描述了按组织学亚型的生存估计。在组织学亚型内,使用单变量 Cox 回归评估病理分期、淋巴结浸润、软组织边缘、年龄和性别作为癌症特异性生存率和总体生存率的预测因素。
中位随访时间为 44 个月。在 104 例患者死亡中,60 例死于疾病。我们没有发现鳞状细胞癌和鳞状分化患者生存曲线之间存在统计学显著差异(对数秩总体生存率 p = 0.6,癌症特异性生存率 p = 0.17)。阳性软组织边缘与单纯鳞状细胞癌患者的癌症特异性生存率(HR 6.92,95%CI 2.98-16.10,p ≤0.0005)和总体生存率(HR 3.68,95%CI 1.84-7.35,p ≤0.0005)较差相关。在具有鳞状分化的患者中,盆腔淋巴结病与总体生存率降低相关(HR 2.52,95%CI 1.33-4.77,p = 0.004)和癌症特异性生存率(HR 3.23,95%CI 1.57-6.67,p = 0.002)。
在接受根治性膀胱切除术和盆腔淋巴结清扫术的患者中,鳞状细胞癌和鳞状分化患者的癌症特异性生存率或总体生存率似乎没有差异。具有鳞状分化和肿瘤转移至盆腔淋巴结的患者应更密切随访,并考虑辅助治疗以提高生存率。广泛的手术切除对于实现局部肿瘤控制和提高鳞状细胞癌患者的生存率至关重要。